Show simple item record

dc.contributor.authorFlotte, Terence R.
dc.date2022-08-11T08:10:13.000
dc.date.accessioned2022-08-23T16:59:53Z
dc.date.available2022-08-23T16:59:53Z
dc.date.issued2019-01-10
dc.date.submitted2019-07-10
dc.identifier.citation<p>Hum Gene Ther. 2019 Jan;30(1):1-2. doi: 10.1089/hum.2018.29080.trf. <a href="https://doi.org/10.1089/hum.2018.29080.trf">Link to article on publisher's site</a></p>
dc.identifier.issn1043-0342 (Linking)
dc.identifier.doi10.1089/hum.2018.29080.trf
dc.identifier.pmid30628861
dc.identifier.urihttp://hdl.handle.net/20.500.14038/43688
dc.description.abstractThe continued rapid progress of human gene and cell therapy in the latter half of the 2010s is fueled by the maturation of gene and cell therapy platforms, improvements in manufacturing capabilities, and an investment climate in the United States and Europe that has been very favorable to biotechnology and pharmaceutical industries engaged in gene therapy product development. Many of these factors are likely to continue in 2019, although some of them may bear further examination. Given what is known in late 2018, the following predictions are put forward for consideration.
dc.language.isoen_US
dc.relation<p><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=30628861&dopt=Abstract">Link to Article in PubMed</a></p>
dc.relation.urlhttps://doi.org/10.1089/hum.2018.29080.trf
dc.subjectGenetics and Genomics
dc.subjectTherapeutics
dc.titleTop Five Gene Therapy Stories of 2019
dc.typeEditorial
dc.source.journaltitleHuman gene therapy
dc.source.volume30
dc.source.issue1
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/peds_pp/270
dc.identifier.contextkey14897104
html.description.abstract<p>The continued rapid progress of human gene and cell therapy in the latter half of the 2010s is fueled by the maturation of gene and cell therapy platforms, improvements in manufacturing capabilities, and an investment climate in the United States and Europe that has been very favorable to biotechnology and pharmaceutical industries engaged in gene therapy product development. Many of these factors are likely to continue in 2019, although some of them may bear further examination. Given what is known in late 2018, the following predictions are put forward for consideration.</p>
dc.identifier.submissionpathpeds_pp/270
dc.contributor.departmentHorae Gene Therapy Center
dc.contributor.departmentDepartment of Pediatrics
dc.source.pages1-2


This item appears in the following Collection(s)

Show simple item record